2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow pegylated interferon-alfa 2a: new trials by email Literature Review of pegylated interferon-alfa 2a trials Research Report on pegylated interferon-alfa 2a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection VIR-2218, pegylated interferon-alfa 2a - Chronic Hepatitis B | Phase 2 | Completed | Vir Biotechnology, Inc. | 84 | 2020-07-03 | 2026-04-16 |
| Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera pegylated interferon-alfa 2a - Polycythemia Vera | Phase 2 | Completed | PV-Nord | 40 | 2004-09-01 | 2015-10-21 |
Hepatitis (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1)
PV-Nord (1) · Vir Biotechnology, Inc. (1)
Australia (1) · France (1) · Hong Kong (1) · Malaysia (1) · New Zealand (1) · South Korea (1) · Thailand (1)
Bruno Cassinat, MD (1) · Christine Chomienne, MD, PhD (1) · Jean-Francois Bernard, MD (1) · Jean-Jacques Kiladjian, MD (1) · Marie-Jose Grange, MD (1) · Nathalie Cambier, MD (1) · Philippe Rousselot, MD (1) · Pierre Fenaux, MD, PhD (1) · Sylvia Bellucci, MD (1)